Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)

被引：0
|
作者：
Vienne, A. [1 ]
Collet, L. [2 ]
Chevalier, T. [3 ]
Borel, C. [4 ]
Tardy, M. P. [5 ]
Huguet, F. [6 ]
Richard, S. [7 ]
Salas, S. [3 ]
Saada-Bouzid, E. [5 ]
Fayette, J. [2 ]
Daste, A. [1 ]
机构：
[1] CHU Bordeaux Hop St Andre, Gironde, Bordeaux, France
[2] Ctr Leon Berard, Med, Lyon, France
[3] AP HM, Med Oncol, Marseille, France
[4] ICANS Inst Cancerol Strasbourg Europe, Med Oncol Dept, Strasbourg, France
[5] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France
[6] Hop Tenon, Dept Radiat Oncol, Paris, France
[7] Hosp Tenon, AP HP, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
925P
引用
收藏
页码：S666 / S666
页数：1
相关论文
共 50 条
  • [1] Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
    Vienne, Agathe
    Collet, Laetitia
    Chevalier, Thomas
    Borel, Christian
    Tardy, Magalie
    Huguet, Florence
    Richard, Sandrine
    Salas, Sebastien
    Saada-Bouzid, Esma
    Fayette, Jerome
    Daste, Amaury
    BMC CANCER, 2023, 23 (01)
  • [2] Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
    Agathe Vienne
    Laetitia Collet
    Thomas Chevalier
    Christian Borel
    Magalie Tardy
    Florence Huguet
    Sandrine Richard
    Sebastien Salas
    Esma Saada-Bouzid
    Jerome Fayette
    Amaury Daste
    BMC Cancer, 23
  • [3] Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
    Economopoulou, Panagiota
    Gavrielatou, Niki
    Papaxoinis, George
    Kotsantis, Ioannis
    Pantazopoulos, Anastasios
    Anastasiou, Maria
    Kavourakis, George
    Gkolfinopoulos, Stavros
    Psyrri, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs) plus /- chemotherapy (CT) and prebiotic inulin in the PRINCESS study
    Galizia, D.
    Minei, S.
    Abbona, A.
    Paccagnella, M.
    Piccinno, G.
    Polidori, A.
    De Zarlo, L.
    Albini, M.
    Rizzo, A.
    Campanella, D.
    Cappello, G.
    Enrico, F.
    Bondi, S.
    Segata, N.
    Gregorc, V.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S560 - S560
  • [5] Efficacy of cetuximab based chemotherapy after immunotherapy treatments (IT) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Garralda, E.
    Villacampa Javierre, G.
    Feliu, B.
    Martinez, S.
    Gutierrez, R.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 59 - 59
  • [6] Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
    Vellanki, Paz J.
    Marur, Shanthi
    Bandaru, Pradeep
    Mishra-Kalyani, Pallavi Shruti
    By, Kunthel
    Girvin, Andrew
    Chatterjee, Somak
    Singh, Harpreet
    Keegan, Patricia
    Larkins, Erin A.
    Cross, Frank
    Pazdur, Richard
    Theoret, Marc R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Saleh, Khalil
    Daste, Amaury
    Martin, Nicolas
    Pons-Tostivint, Elvire
    Auperin, Anne
    Herrera-Gomez, Ruth Gabriela
    Baste-Rotllan, Neus
    Bidault, Francois
    Guigay, Joel
    Le Tourneau, Christophe
    Saada-Bouzid, Esma
    Even, Caroline
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 123 - 129
  • [8] Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
    Carinato, H.
    Burgy, M.
    Fischbach, C.
    Kalish-Weindling, M.
    Pabst, L.
    Frasie, V.
    Thiery, A.
    Coliat, P.
    Demarchi, M. F.
    Petit, T.
    Borel, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S668 - S668
  • [9] Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs)
    Syeed, Z.
    Forster, M.
    Boukovinas, I.
    Nutting, C.
    Carnell, D.
    Urbano, T. Guerrero
    Sibtain, A.
    Kalavrezos, N.
    Patel, G.
    Al Bakir, M.
    Arkenau, H-T.
    Levva, S.
    Gonnet, P.
    Morelli, C.
    Guerriero, S.
    Rofei, M.
    Formica, V.
    Patrikidou, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S798 - S798
  • [10] TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Guigay, Joel
    Fayette, Jerome
    Mesia, Ricard
    Lafond, Cedrik
    Saada-Bouzid, Esma
    Geoffrois, Lionnel
    Martin, Laurent
    Cupissol, Didier
    Capitain, Olivier
    Castanie, Helene
    Vansteene, Damien
    Schafhausen, Philippe
    Arvis, Catherine Dubos
    Even, Caroline
    Sire, Christian
    Delhommeau, Melissa
    Michel, Cecile
    Bourhis, Jean
    Keilholz, Ulrich
    Auperin, Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345